Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease. In addition, the company’s preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson’s disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Navacaprant Setback | Neumora's lead drug for major depressive disorder faces challenges after KOSTAL-1 trial failure, prompting reevaluation of its $2.2 billion peak sales forecast |
Pipeline Potential | Explore Neumora's diverse neuroscience portfolio targeting bipolar depression, schizophrenia, and Alzheimer's-related agitation, offering multiple growth avenues |
Financial Health | Despite strong cash reserves, Neumora grapples with negative free cash flow and high debt, presenting a complex financial picture for investors |
Market Outlook | Analysts maintain cautious optimism with price targets ranging from $7 to $29, reflecting the uncertain yet potentially lucrative neuroscience market |
Metrics to compare | NMRA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNMRAPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.9x | −3.8x | −0.5x | |
PEG Ratio | −0.04 | 0.02 | 0.00 | |
Price/Book | 1.3x | 3.5x | 2.6x | |
Price / LTM Sales | - | 2.1x | 3.3x | |
Upside (Analyst Target) | 208.2% | 69.2% | 43.5% | |
Fair Value Upside | Unlock | 5.9% | 6.8% | Unlock |